SenesTech, a biotechnology company specializing in fertility control products for pests, filed an amended annual report for the fiscal year ended December 31, 2023. The report, filed with the SEC on February 21, 2024, was amended to include additional information required for the upcoming annual meeting of stockholders. The company's common stock is traded on the Nasdaq Capital Market under the symbol SNES. As of June 30, 2023, the market value of SenesTech's common stock held by non-affiliates was approximately $3.32 million, with 247,040 shares outstanding. By February 20, 2024, the number of outstanding shares had increased to 5,144,632. The report details the company's executive leadership, including the CEO Joel L. Fruendt, and the board of directors, highlighting their qualifications and contributions to the company's strategic...Show More

SenesTech, a biotechnology company specializing in fertility control products for pests, filed an amended annual report for the fiscal year ended December 31, 2023. The report, filed with the SEC on February 21, 2024, was amended to include additional information required for the upcoming annual meeting of stockholders. The company's common stock is traded on the Nasdaq Capital Market under the symbol SNES. As of June 30, 2023, the market value of SenesTech's common stock held by non-affiliates was approximately $3.32 million, with 247,040 shares outstanding. By February 20, 2024, the number of outstanding shares had increased to 5,144,632. The report details the company's executive leadership, including the CEO Joel L. Fruendt, and the board of directors, highlighting their qualifications and contributions to the company's strategic direction. The executive compensation section reveals that CEO Joel L. Fruendt received a total compensation of $343,044 in 2023, while EVP and CFO Thomas C. Chesterman received $261,431. The report also outlines the company's equity compensation plans, with 7,804,193 securities to be issued upon the exercise of outstanding options, warrants, and rights. SenesTech's board of directors has a majority of independent members, as required by Nasdaq listing standards. The company has adopted policies for the pre-approval of audit and non-audit services to ensure the independence of its auditors. The financial statements and schedules, along with a list of exhibits, are provided in the report, offering transparency into the company's financial and operational status.